Featured Publications
Psychedelic Medicine: Creating an Introductory Course for Mental Health Professionals and Trainees
Prueitt WL, Sloshower J. Psychedelic Medicine: Creating an Introductory Course for Mental Health Professionals and Trainees. Academic Psychiatry 2022, 47: 74-77. PMID: 35616783, PMCID: PMC9134971, DOI: 10.1007/s40596-022-01662-9.Peer-Reviewed Original ResearchResearch abuses against people of colour and other vulnerable groups in early psychedelic research
Strauss D, de la Salle S, Sloshower J, Williams MT. Research abuses against people of colour and other vulnerable groups in early psychedelic research. Journal Of Medical Ethics 2021, 48: 728-737. PMID: 34253622, DOI: 10.1136/medethics-2021-107262.Peer-Reviewed Original ResearchSubstance use disordersDrug administration conditionsPsychedelic researchMental health issuesEthnicity of participantsUse disordersMental healthHealth issuesVulnerable populationsPsychedelic medicineVulnerable groupsResearch abusesFuture studiesAdministration conditionsAbuseCurrent ethical standardsFirst waveVariables of interestParticipantsFindingsPsilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame
Sloshower J, Guss J, Krause R, Wallace R, Williams M, Reed S, Skinta M. Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame. Journal Of Contextual Behavioral Science 2020, 15: 12-19. DOI: 10.1016/j.jcbs.2019.11.002.Peer-Reviewed Original ResearchMajor depressive disorderClinical trialsDepressive disorderPsychedelic-assisted therapyPsilocybin-assisted therapyCommitment TherapyRecent clinical trialsSmall clinical trialsDosing sessionsNeurobiological actionsPsilocybin therapyEvidence-based modelTherapyTherapy protocolsPsilocybin experiencePotential synergismDrug experienceTherapy sessionsTreatment modelClinical processesTrialsDisordersPsychological flexibilityMechanisms of changeACT processesIntegrating Psychedelic Medicines and Psychiatry: Theory and Methods of a Model Clinic
Sloshower J. Integrating Psychedelic Medicines and Psychiatry: Theory and Methods of a Model Clinic. 2018, 113-132. DOI: 10.1007/978-3-319-76720-8_7.ChaptersHealing paradigmPsychiatric practiceCurrent psychiatric practicePsychedelic substancesSymptom-focused treatmentEthical challengesReductionist tendenciesCritical dialogueHuman beingsPsychedelic medicineReflexive mannerModel clinicTherapeutic narrativesMental illnessParadigm integrationBiological paradigmMedical SciencesSufferingRelated practicesKnowledge generationPassive recipientsPracticeEnergetic domainsSuch challengesParadigmNeuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics
Schindler EAD, Wallace RM, Sloshower JA, D’Souza D. Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics. Frontiers In Pharmacology 2018, 9: 177. PMID: 29545753, PMCID: PMC5838010, DOI: 10.3389/fphar.2018.00177.Peer-Reviewed Original ResearchCluster headacheClassic serotonergic psychedelicsPersistent therapeutic effectEffects of psychedelicsPotential long-term effectsPsychedelic drugsSystem involvementHeadache disordersTherapeutic resultsPsychedelic-assisted therapyDrug classesTherapeutic effectLong-term effectsMood disordersTherapeutic benefitMethodologic considerationsNeuropsychiatric disordersNeuroendocrine systemPsychedelic effectsHeadacheBeneficial effectsSerotonergic psychedelicsDisordersDrugsRecent reportsPsilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial
Sloshower J, Skosnik P, Safi-Aghdam H, Pathania S, Syed S, Pittman B, D’Souza D. Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. Journal Of Psychopharmacology 2023, 37: 698-706. PMID: 36938991, DOI: 10.1177/02698811231154852.Peer-Reviewed Original ResearchConceptsMajor depressive disorderAntidepressant effectsDepressive disorderSevere major depressive disorderPsilocybin-assisted therapyEarly phase studiesQuality of lifeClinical improvementDosing sessionsMajor depressionPsilocybin administrationPlacebo effectPsychotherapeutic supportPlaceboTherapy effectsStudy periodPsychotherapy studiesFurther studiesSignificant differencesDepressionDosingTherapyHigh rateEffect sizeDegree of changeSub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms
Skosnik P, Sloshower J, Safi-Aghdam H, Pathania S, Syed S, Pittman B, D’Souza D. Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms. Journal Of Psychopharmacology 2023, 37: 687-697. PMID: 37392016, DOI: 10.1177/02698811231179800.Peer-Reviewed Original ResearchConceptsAntidepressant effectsTheta powerMajor depressive disorderEffects of psilocybinSub-acute effectsLong-term alterationsMeasures of depressionSingle doseDepressive disorderMajor depressionDepressive symptomsPlaceboSymptoms 2Depression symptomsEEG theta powerNeural plasticityNeuroplasticityEEG biomarkersSymptomsSerotonergic psychedelicsPotential mechanismsDepressionSustained changesElectroencephalographic correlatesPsilocybinThe DEA report on ayahuasca risks: “Science” in service of prohibition?
Labate B, Ermakova A, Sloshower J, Galvão-Coelho N, Palhano-Fontes F, Antunes H, Loures de Assis G, Cavnar C, de Araújo D, Ribeiro S. The DEA report on ayahuasca risks: “Science” in service of prohibition? Journal Of Psychedelic Studies 2023, 7: 81-89. DOI: 10.1556/2054.2023.00279.Peer-Reviewed Original ResearchSingle-Dose Psilocybin Treatment for Major Depressive Disorder
Raison C, Sanacora G, Woolley J, Heinzerling K, Dunlop B, Brown R, Kakar R, Hassman M, Trivedi R, Robison R, Gukasyan N, Nayak S, Hu X, O’Donnell K, Kelmendi B, Sloshower J, Penn A, Bradley E, Kelly D, Mletzko T, Nicholas C, Hutson P, Tarpley G, Utzinger M, Lenoch K, Warchol K, Gapasin T, Davis M, Nelson-Douthit C, Wilson S, Brown C, Linton W, Johnson M, Ross S, Griffiths R. Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA 2023, 330: 843-853. PMID: 37651119, PMCID: PMC10472268, DOI: 10.1001/jama.2023.14530.Peer-Reviewed Original ResearchConceptsMajor depressive disorderSheehan Disability Scale scoresAdverse eventsDisability scale scorePsilocybin treatmentDay 43Scale scoreSecondary outcomesSingle doseDepressive disorderExclusion criteriaPsychological supportMontgomery-Asberg Depression Rating Scale scoreSerious treatment-emergent adverse eventsDay 8Key secondary outcome measuresTreatment-emergent adverse eventsDepression Rating Scale scoresActive substance use disorderFifth Edition diagnosisIdentical-appearing capsulesOverall adverse eventsPhase 2 trialSerious adverse eventsSevere adverse events
2024
Letter to the Editors.
Guss J, Sloshower J. Letter to the Editors. Psychodynamic Psychiatry 2024, 52: 237-238. PMID: 38829229, DOI: 10.1521/pdps.2024.52.2.237.Peer-Reviewed Original ResearchPsychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial
Sloshower J, Zeifman R, Guss J, Krause R, Safi-Aghdam H, Pathania S, Pittman B, D’Souza D. Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial. Scientific Reports 2024, 14: 8833. PMID: 38632313, PMCID: PMC11024097, DOI: 10.1038/s41598-024-58318-x.Peer-Reviewed Original ResearchConceptsPsilocybin-assisted therapyPsychological flexibilityDepression severityModerate to severe MDDSpectrum of neuropsychiatric conditionsTarget psychological flexibilityIncrease psychological flexibilityMental health conditionsManualized psychotherapyPsilocybin treatmentSevere MDDDepressive disorderExperiential acceptanceCommitment therapyDosing sessionsNeuropsychiatric conditionsPsychedelic trialsPlacebo-controlled trialWithin-subjectMDDPsilocybinAdministered placeboPlacebo-controlledDepressionClinical samples
2020
The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame)
Guss, J., Krause, R. & Sloshower, J. (2020, August 13). The Yale Manual for Psilocybin- Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame). https://doi.org/10.31234/osf.io/u6v9yPeer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2017
Online Sales of Unscheduled Pharmaceutical Agents
Gupta S, Wallace R, Sloshower J. Online Sales of Unscheduled Pharmaceutical Agents. Journal Of Addiction Medicine 2017, 11: 411-412. PMID: 28742625, DOI: 10.1097/adm.0000000000000342.Peer-Reviewed Original ResearchConceptsSignificant withdrawal syndromeUse of tianeptineMu-opioid receptorsMajor depressive disorderPharmaceutical agentsWithdrawal syndromeTricyclic antidepressantsDepressive disorderGeneral populationHealth storesDrug AdministrationMedical providersHigh dosesTianeptineDietary supplementsUnmonitored useCognition enhancersAntidepressantsDosesResearch chemicalsUnited StatesDiscontinuationPatientsSignificant harmSertraline
2014
Pathways of HIV Risk and Vulnerability Among New Female Sex Workers in Northern Karnataka, India
Sloshower, J. (2014). “Pathways of HIV Risk and Vulnerability Among New Female Sex Workers in Northern Karnataka, India.” EliScholar – Yale Medicine Thesis Digital Library.Books
2013
Capturing Suffering: Ethical Considerations of Bearing Witness and the Use of Photography
Sloshower J. Capturing Suffering: Ethical Considerations of Bearing Witness and the Use of Photography. The International Journal Of The Image 2013, 3: 11-22. DOI: 10.18848/2154-8560/cgp/v03i02/44079.Peer-Reviewed Original Research
2012
Descent into quiet chaos: the story of Mr. F.
Sloshower J. Descent into quiet chaos: the story of Mr. F. Connecticut Medicine 2012, 76: 423-4. PMID: 23248868.Peer-Reviewed Case Reports and Technical NotesDescribing the content of primary care: limitations of Canadian billing data
Katz A, Halas G, Dillon M, Sloshower J. Describing the content of primary care: limitations of Canadian billing data. BMC Primary Care 2012, 13: 7. PMID: 22335900, PMCID: PMC3305652, DOI: 10.1186/1471-2296-13-7.Peer-Reviewed Original ResearchConceptsPrimary care clinical encountersPrimary care encountersData collection formFirst Canadian studyClinical encountersPrimary careCare encountersPatient encountersCollection formPrimary care reform initiativesWay family physiciansPrimary care physiciansPrimary care dataICD-9 codesFamily practice clinicComprehensive patient careComplexity of careICD-9 codingCanadian StudyICD-9 coding systemPhysician-patient interactionHealth care systemCare physiciansPractice clinicsDiagnostic codes
2010
Negotiating Pharmaceutical Politics and Ethics: Democracy, Citizenship and Medical Activism in Thailand
Sloshower, J. (2010). Negotiating Pharmaceutical Politics and Ethics: Democracy, Citizenship and Medical Activism in Thailand. Lambert Academic PublishingBooks